Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis

There is an unmet need for disease-modifying therapies to improve ambulatory function in disabled subjects with multiple sclerosis. Assess the effects of natalizumab on ambulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple scler...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	PloS one Ročník 8; číslo 1; s. e53297
Hlavní autoři:	Cadavid, Diego, Jurgensen, Stephanie, Lee, Sophia
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Public Library of Science 04.01.2013 Public Library of Science (PLoS)
Témata:	Adult Antibodies, Monoclonal, Humanized - therapeutic use Autoimmune diseases Brain Care and treatment Clinical trials Disability Dosage and administration Feet Female Humans Immunotherapy Impact analysis Inflammation Interferon Interferon beta-1a Interferon-beta - therapeutic use Male Medicine Middle Aged Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Chronic Progressive - drug therapy Multiple Sclerosis, Chronic Progressive - physiopathology Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - physiopathology Natalizumab Neurology Patient outcomes Quality of life Retrospective Studies Reviews Studies Treatment Outcome Walking United States United States > US Massachusetts
ISSN:	1932-6203, 1932-6203
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!